BIOXCEL THERAPEUTICS INC's ticker is BTAI and the CUSIP is 09075P105. A total of 95 filers reported holding BIOXCEL THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 0.94 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $759 | -94.7% | 300 | -86.2% | 0.00% | – |
| Q2 2023 | $14,436 | -56.4% | 2,169 | +22.2% | 0.00% | – |
| Q1 2023 | $33,112 | -40.9% | 1,775 | -32.0% | 0.00% | – |
| Q4 2022 | $56,000 | +64.7% | 2,611 | -8.2% | 0.00% | – |
| Q3 2022 | $34,000 | -27.7% | 2,844 | -18.8% | 0.00% | – |
| Q2 2022 | $47,000 | -50.0% | 3,502 | -10.0% | 0.00% | – |
| Q1 2022 | $94,000 | +34.3% | 3,890 | +13.2% | 0.00% | – |
| Q4 2021 | $70,000 | -84.9% | 3,437 | -77.6% | 0.00% | -100.0% |
| Q3 2021 | $465,000 | +14.5% | 15,322 | +9.6% | 0.00% | 0.0% |
| Q2 2021 | $406,000 | -5.1% | 13,985 | +41.2% | 0.00% | 0.0% |
| Q1 2021 | $428,000 | +107.8% | 9,901 | +122.1% | 0.00% | 0.0% |
| Q4 2020 | $206,000 | +35.5% | 4,458 | +28.9% | 0.00% | – |
| Q3 2020 | $152,000 | +94.9% | 3,458 | +134.8% | 0.00% | – |
| Q2 2020 | $78,000 | +100.0% | 1,473 | -19.2% | 0.00% | – |
| Q1 2020 | $39,000 | – | 1,823 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| APIS CAPITAL ADVISORS, LLC | 40,000 | $836,000 | 1.01% |
| ACT CAPITAL MANAGEMENT, LLC | 20,000 | $418,000 | 0.44% |
| Knoll Capital Management, LLC | 20,000 | $418,000 | 0.26% |
| Artemis Investment Management LLP | 1,428,228 | $29,855,000 | 0.24% |
| Rubric Capital Management LP | 268,528 | $5,615,000 | 0.20% |
| Virtus ETF Advisers LLC | 7,713 | $161,000 | 0.07% |
| BOOTHBAY FUND MANAGEMENT, LLC | 107,700 | $2,252,000 | 0.05% |
| PDT Partners, LLC | 28,031 | $586,000 | 0.05% |
| AllSquare Wealth Management LLC | 3,162 | $66,000 | 0.04% |
| Hennion & Walsh Asset Management, Inc. | 35,221 | $736,000 | 0.04% |